An open-label phase I study to investigate the drug-drug interaction between GR-MD-02 and midazolam

Trial Profile

An open-label phase I study to investigate the drug-drug interaction between GR-MD-02 and midazolam

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2015

At a glance

  • Drugs GR MD 02 (Primary) ; Midazolam
  • Indications Non-alcoholic steatohepatitis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 May 2015 New trial record
    • 14 May 2015 According to a Galectin Therapeutics media release, this study was required by the US FDA. The lack of a drug interaction in this study will permit Galectin to expand the number of patients eligible for its Phase 2 clinical trial.
    • 14 May 2015 Results published in a Galectin Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top